BRTX vs LIN · rev $401.0K vs P/E 34, rev $33.99B
BioRestorative Therapies Inc (BRTX) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
BioRestorative Therapies Inc (BRTX) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported BRTX revenue for 2024-12-31 was $401.0K. Net income was -$9.0M. Revenue was up 175.0% from 2023-12-31 to 2024-12-31. BRTX currently screens at market cap $10.2M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
BRTX currently screens at market cap $10.2M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the BRTX and LIN stock pages for the full models.
Not investment advice.